Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06549816
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-22
Brief Title:
A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors
Sponsor:
None
Organization:
None
Study Overview
Official Title:
An Open-label Phase 1 Study to Investigate the Safety and Pharmacokinetics of SGN-B6A in Chinese Subjects With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will look at a drug called sigvotatug vedotin SGN-B6A to find out whether it is safe for Chinese participants who have solid tumors It will study sigvotatug vedotin to find out what its side effects are A side effect is anything the drug does besides treating cancer It will also study how do Chinese participants body interact with sigvotatug vedotin
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None